User login

We offer our registered users tailored information, free online courses and exclusive content.

You have an old EXCEMED account ...

Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?

... or you lost your password?

Congress Report: Highlights from the 26th European Meeting on Hypertension and Cardiovascular Protection

Congress Report: Highlights from the 26th European Meeting on Hypertension and Cardiovascular Protection
  • Cardiometabolic
  • Hypertension

Author

Resource type

Article

Tags

Congress report
European Society of Hypertension
ESH
new technology
Adherence
Obesity
Diabetes
Hypertension

Harry Struijker-Boudier shares his highlights from this annual meeting, held at the Palais des Congrès, Paris, 10–13 June 2016

Devices, not pharmaceuticals, dominated exhibit space; clinical trials, drug adherence strategies and the obesity/diabetes/hypertension combination were all highlights in the scientific programme


The programme, devised by the French organizing committee and the scientific council of the European Society of Hypertension (ESH), covered not just hypertension, but also cardiovascular and metabolic disorders related to hypertension.

Innovations

New technologies, such as innovative devices, new communicating tools and biological “omics” research were a particular feature of this meeting, not just in the scientific program, but also on the exhibition floor.

Exhibition space at previous ESH meetings has been dominated by the pharmaceutical industry; in contrast, the majority of exhibitors at this meeting were from the device industry.

Technology to measure arterial stiffness was a particular highlight, perhaps not surprising in Paris, given the great contributions of the “Paris School” to arterial stiffness research.

Clinical trials

One of the traditional focus points of ESH meeting scientific programmes is the review of recent clinical trials.

This year, clinical trials on renal denervation in the management of hypertension were featured, as well as the impact of the recent Systolic Blood Pressure Intervention Trial (SPRINT) on optimal targets for hypertension treatment and the Heart Outcomes Prevention Evaluation-3 (HOPE-3) trial on the use of statins as a more generalized risk-reduction strategy in hypertensive patients.

In particular, the Hot Topic sessions and Teaching Seminars for these trials drew large audiences and lively discussions.

Adherence workshop

A well-attended topical workshop was devoted to drug adherence. Poor drug adherence is still a major cause of poor results in optimized treatment of hypertension. The speakers in this workshop reviewed various methods to assess and improve therapeutic adherence.

Combination health problems

Various sessions dealt with the obesity/diabetes/hypertension combination as a major global emerging public health problem.

Some sessions were held in association with Latin American and Arabian countries, where this combination is now a primary cardiovascular risk factor.

Terms of use

This is a copyrighted resource for the sole purpose of education. Resource may be used for classroom training only and must remain as is, including the branding and EXCEMED logo. It is backed by a publishing license, signed by the author.